Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model.
Avian-origin influenza represents a global public health concern. In 2013, the H10N8 virus caused documented human infections for the first time. Currently, there is no approved vaccine against H10 influenza. Recombinant virus-like particles (VLPs) represent a promising vaccine approach. In this study, we evaluated H10 VLPs containing hemagglutinin from H10N8 virus as an experimental vaccine in a ferret challenge model. In addition, we evaluated quadri-subtype VLPs co-localizing H5, H7, H9 and H10 subtypes. Both vaccines elicited serum antibody that reacted with the homologous H10 derived from H10N8 virus and cross-reacted with the heterologous H10N1 virus. Quadri-subtype vaccine also elicited serum antibody to the homologous H5, H7, and H9 antigens and cross-reacted with multiple clades of H5N1 virus. After heterologous challenge with the H10N1 virus, all vaccinated ferrets showed significantly reduced titers of replicating virus in the respiratory tract indicating protective effect of vaccination with either H10 VLPs or with quadri-subtype VLPs.
Medigen, Inc., 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA. Electronic address: ppushko@medigen-usa.com.
Peter
P
Pushko
Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA, USA.
Xiangjie
X
Sun
Medigen, Inc., 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA.
Irina
I
Tretyakova
Medigen, Inc., 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA.
Rachmat
R
Hidajat
Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA, USA.
Joanna A
JA
Pulit-Penaloza
Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA, USA.
Jessica A
JA
Belser
Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA, USA.
Taronna R
TR
Maines
Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA, USA.
Terrence M
TM
Tumpey
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D003429:Cross Reactions; D005289:Ferrets; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology*; D006801:Humans; D065926:Influenza A Virus, H10N8 Subtype / Q000276:immunology*; D053124:Influenza A Virus, H5N1 Subtype / Q000145:classification / Q000276:immunology; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control*; D058425:Vaccines, Virus-Like Particle / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D014779:Virus Replication
D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; D058425:Vaccines, Virus-Like Particle; C109963:hemagglutinin, avian influenza A virus
Baculovirus; H10N8; Influenza; Recombinant vaccine; VLP; Virus-like particles
MBio. 2014 Dec 09;5(6):e02107
25491354
PLoS One. 2013 Apr 30;8(4):e62496
23638099
Virology. 2016 Jan;487:163-71
26529299
Emerg Infect Dis. 2006 Jan;12(1):61-5
16494719
Vaccine. 2016 Mar 18;34(13):1575-81
26868083
Vaccine. 2007 May 22;25(21):4283-90
17403562
Vaccine. 2011 Aug 11;29(35):5911-8
21723354
PLoS Pathog. 2013;9(10):e1003657
24130481
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
20463105
PLoS One. 2010 Feb 11;5(2):e9161
20161790
J Infect Dis. 2008 Feb 15;197(4):580-3
18237269
Nat Rev Immunol. 2007 Apr;7(4):267-78
17363960
Vaccine. 2007 May 10;25(19):3871-8
17337102
J Virol. 2009 Jun;83(11):5726-34
19321609
J Virol. 2015 Oct 28;90(2):851-61
26512088
N Engl J Med. 2013 May 16;368(20):1888-97
23577628
Vaccine. 2010 Jul 5;28(30):4771-6
20470801
J Infect. 2014 Mar;68(3):205-15
24406432
MMWR Morb Mortal Wkly Rep. 2010 Aug 27;59(33):1057-62
20798667
Vaccine. 2009 Aug 13;27(37):5091-5
19577636
Vaccine. 2015 Apr 27;33(18):2152-8
25772674
PLoS One. 2009 Jun 24;4(6):e6032
19554101
Vaccine. 2015 Sep 11;33(38):4975-82
26207590
Science. 2012 Jan 27;335(6067):400-1
22282787
Nat Rev Drug Discov. 2015 Mar;14(3):167-82
25722244
Vaccine. 2015 Feb 25;33(9):1102-6
25604801
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7558-63
18508975
J Virol. 2005 Sep;79(18):11788-800
16140756
Ther Adv Vaccines. 2015 Jul;3(4):97-108
26478817
Curr Opin Mol Ther. 2005 Feb;7(1):24-9
15732526
Vaccine. 2006 Nov 10;24(44-46):6742-6
17069939
Curr Top Microbiol Immunol. 2015;386:301-21
25007847
Nat Rev Microbiol. 2011 Jul 11;9(8):590-603
21747392
Curr Top Microbiol Immunol. 2009;333:269-89
19768411
Viral Immunol. 2005;18(1):244-51
15802970
Clin Microbiol Rev. 2012 Apr;25(2):344-61
22491775
Vaccine. 2005 Dec 30;23(50):5751-9
16143432
Emerg Infect Dis. 2009 Aug;15(8):1252-9
19751587
Sci Rep. 2016 Jan 19;6:19474
26782141
Emerg Infect Dis. 2015 Aug;21(8):1372-8
26196098
Viruses. 2016 Apr 12;8(4):96
27077877
Virology. 2013 Jul 20;442(1):67-73
23618102
Lancet. 2014 Feb 22;383(9918):676-7
24508318
N Engl J Med. 2006 Mar 30;354(13):1343-51
16571878
MBio. 2015 Jul 21;6(4):e01044
26199334